The Latest Cardiac and Vascular News
IRVINE, Calif.–(BUSINESS WIRE)–Vascular Dynamics, Inc. (VDI), a privately held medical device company focused on developing game-changing endovascular device-based solutions for patients suffering from cardiovascular conditions, has announced that encouraging early results for its heart failure clinical trial have been presented. The company has also announced the addition of Stan Rabinovich to […]
MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update. “Having completed the merger with PHPrecisionMed […]
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update. “We continue to work closely with our existing clinical trial sites, […]
— Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO — — Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior advisor – ANN ARBOR, […]
Continued enrollment progress in Phase 3 REVERSE-IT clinical trial for Bentracimab Signed commercial supply agreement with BioVectra to support development and commercialization of lead product candidate bentracimab Completed underwritten public offering of common stock yielding $60.1 million in net proceeds May 13, 2021 04:00 PM Eastern Daylight Time MALVERN, Pa. […]
BRADENTON, Fla.–(BUSINESS WIRE)–PaceMate™, the leading digital technology company in healthcare data management, is pleased to announce the appointment of seven cardiac electrophysiologist professionals as members of the company’s medical advisory board. As PaceMate™ continues forward in its mission to advance efficient digital healthcare solutions through innovative technology and its compassion-driven […]
– Operating loss decreased vs. Q1 2020 – Net loss increased vs. Q1 2020 – ZanthoSyn® revenues decreased vs. Q1 2020 – Company pursuing multiple funding opportunities HONOLULU, May 14, 2021 /PRNewswire/ — Cardax, Inc. (OTCQB:CDXI) reported its Q1 2021 results. Highlights: Financial Results. Operating loss decreased from $906,031 in Q1 2020 to $771,312 in Q1 2021 […]
WARRINGTON, Pa., May 13, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates. Key Business and Financial Updates Expanded the participating […]
SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today reported financial results for the first quarter of 2021 and filed its quarterly report on Form 10-Q for the three months ended March […]
– Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery – Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder – Improved financial position with private placement and access to new credit facility – Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., May […]
